Nepexto (Etanercept)

Etanercept is a fusion protein that binds to tumor necrosis factor‑alpha (TNF‑α), a key cytokine driving inflammation. By sequestering TNF‑α, it blocks the cytokine from interacting with its cellular receptors, thereby dampening the inflammatory cascade and reducing the symptoms associated with autoimmune disorders.

The specific dose and dosing interval for Nepexto are determined by the prescribing healthcare professional based on the patient’s condition, weight, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Etanercept during pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting or continuing therapy.

To request Nepexto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Nepexto (Etanercept) is a soluble receptor fusion protein, whereas many other TNF‑alpha inhibitors are monoclonal antibodies (e.g., adalimumab, infliximab). Etanercept’s mechanism may result in a slightly different safety profile, such as a lower incidence of certain injection‑site reactions, but overall efficacy in approved indications is comparable across the class.

Nepexto should be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 14 days, as recommended by the manufacturer.

Nepexto is given as a subcutaneous injection, typically into the thigh, abdomen, or upper arm. The injection can be performed by a healthcare professional or, after proper training, self‑administered by the patient using the supplied pre‑filled syringe or autoinjector, following aseptic technique.

The most serious risks include severe infections such as tuberculosis or sepsis, the possible development of malignancies (e.g., lymphoma), demyelinating neurological disorders, exacerbation of heart failure, and rare autoimmune phenomena like lupus‑like syndrome. Patients should be monitored closely for any signs of these conditions.

Nepexto is contraindicated in individuals with known hypersensitivity to Etanercept or any of its excipients. It should also be avoided in patients with active, serious infections, uncontrolled heart failure, or those receiving live vaccines. A thorough medical evaluation is required before initiating therapy.